Not yet recruiting
Testosterone Therapy With or Without Finasteride After Spinal Cord Injury: TRT-SCI Trial
NCT07742553· Phase 2/3· VA Office of Research and Development· Source
Not yet recruiting
Exoskeletal-assisted Walking Combined With Transcutaneous Spinal Cord Stimulation: Effect on Imaging and Serum Biomarkers of Skeletal Muscle Mass and Bone Strength.
NCT07418398· VA Office of Research and Development· Source
Recruiting
Pilot Study of Galantamine to Treat Metabolic Syndrome in People With Chronic Traumatic Spinal Cord Injury (SCI)
NCT07625332· Phase 2/3· Northwell Health· Source
Recruiting
AI-Guided Predictions of Blood Pressure Dysregulation Using Perfusion Index as a Novel Biomarker in Persons With Spinal Cord Injury
NCT07699094· James J. Peters Veterans Affairs Medical Center· Source
Recruiting
Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays
NCT07283939· Alliance for Clinical Trials in Oncology· Source
Recruiting
ARC-IM System to Manage Symptomatic Blood Pressure Instability Secondary to Chronic Spinal Cord Injury
NCT07147296· ONWARD Medical, Inc.· Source
Recruiting
Dose Optimization of MDMA-Assisted Therapy for PTSD
NCT06418178· Phase 2· Bronx VA Medical Center· Source
Recruiting
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
NCT06616584· Phase 2/3· SWOG Cancer Research Network· Source
Recruiting
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
NCT06498635· Phase 3· National Cancer Institute (NCI)· Source
Recruiting
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
NCT06418204· Wake Forest University Health Sciences· Source
Active, not recruiting
Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer
NCT06632327· Phase 3· Alliance for Clinical Trials in Oncology· Source
Active, not recruiting
A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).
NCT06551324· Phase 3· Pfizer· Source
Recruiting
A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer
NCT06545955· Phase 3· Ferring Pharmaceuticals· Source
Recruiting
Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer
NCT06510374· Phase 3· Ferring Pharmaceuticals· Source
Recruiting
A Single-Arm Phase II Study of Neoadjuvant Intensified Androgen Deprivation (Leuprolide and Abiraterone Acetate) in Combination With AKT Inhibition (Capivasertib) for High-Risk Localized Prostate Cancer With PTEN Loss
NCT05593497· Phase 2· VA Office of Research and Development· Source
Recruiting
Finding the Best Combination of Brain and Spinal Cord Stimulation With Hand Training After Spinal Cord Injury
NCT06104735· Bronx VA Medical Center· Source
Recruiting
Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)
NCT05485961· Phase 2/3· CSL Behring· Source
Recruiting
Testosterone and Neural Function in Men With Spinal Cord Injury
NCT06130449· Early phase 1· VA Office of Research and Development· Source
Recruiting
Spinal Cord Associative Plasticity for ALS
NCT06172621· VA Office of Research and Development· Source
Active, not recruiting
Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer
NCT06235151· Phase 3· Curium US LLC· Source
Recruiting
Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
NCT06136624· Phase 3· Merck Sharp & Dohme LLC· Source
Recruiting
Preventing Liver Cancer Mortality Through Imaging With Ultrasound vs. MRI
NCT05486572· VA Office of Research and Development· Source
Active, not recruiting
Autonomic Effects of Spinal Cord Stimulation in Spinal Cord Injury
NCT05960448· James J. Peters Veterans Affairs Medical Center· Source
Recruiting
Treatment of Orthostatic Hypotension in SCI
NCT05839652· Phase 4· James J. Peters Veterans Affairs Medical Center· Source
Recruiting
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
NCT05642572· Phase 2· SWOG Cancer Research Network· Source
Active, not recruiting
SELUTION4SFA Trial
NCT05132361· M.A. Med Alliance S.A.· Source
Recruiting
ERP to Improve Functioning in Veterans With OCD
NCT05240924· VA Office of Research and Development· Source
Recruiting
Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer.
NCT05422911· Phase 2· Sun Pharmaceutical Industries Limited· Source
Recruiting
Hearing Impairment, Strategies and Outcomes in VA Emergency Departments
NCT05028972· VA Office of Research and Development· Source
Active, not recruiting
Treatment With Romosozumab Versus Denosumab to Improve Bone Mineral Density and Architecture in Subacute SCI
NCT05101018· Phase 4· James J. Peters Veterans Affairs Medical Center· Source
Active, not recruiting
To Evaluate if Green Tea Can be Effective in Reducing the Progression of Prostate Cancer in Men on Close Monitoring
NCT04597359· Phase 2· ECOG-ACRIN Cancer Research Group· Source
Active, not recruiting
Testing the Use of Targeted Treatment (AMG 510) for KRAS G12C Mutated Advanced Non-squamous Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)
NCT04625647· Phase 2· SWOG Cancer Research Network· Source
Active, not recruiting
Testing the Effects of MK-3475 (Pembrolizumab) With or Without the Usual Chemotherapy Treatment for Patients 70 Years of Age and Older With Advanced Non-small Cell Lung Cancer
NCT04533451· Phase 2· Alliance for Clinical Trials in Oncology· Source
Active, not recruiting
Multi-Center Study of the Effects of Simvastatin on Hepatic Decompensation and Death in Subjects Presenting With High-Risk Compensated Cirrhosis
NCT03654053· Phase 3· VA Office of Research and Development· Source
Active, not recruiting
LIFE-BTK Randomized Controlled Trial
NCT04227899· Abbott Medical Devices· Source
Recruiting
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
NCT04267848· Phase 3· National Cancer Institute (NCI)· Source
Active, not recruiting
NCI COVID-19 in Cancer Patients, NCCAPS Study
NCT04387656· National Cancer Institute (NCI)· Source
Active, not recruiting
Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer
NCT04092283· Phase 3· National Cancer Institute (NCI)· Source
Active, not recruiting
Targeted Treatment for RET Fusion-Positive Advanced Non-Small Cell Lung Cancer (A LUNG-MAP Treatment Trial)
NCT04268550· Phase 2· SWOG Cancer Research Network· Source
Active, not recruiting
A Study of CHeckpoint Inhibitors in Men With prOgressive Metastatic Castrate Resistant Prostate Cancer Characterized by a Mismatch Repair Deficiency or Biallelic CDK12 Inactivation
NCT04104893· Phase 2· VA Office of Research and Development· Source
Active, not recruiting
Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer
NCT03793179· Phase 3· National Cancer Institute (NCI)· Source
Recruiting
Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer
NCT03851445· Phase 2/3· SWOG Cancer Research Network· Source
Recruiting
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
NCT03678025· Phase 3· SWOG Cancer Research Network· Source
Active, not recruiting
Radiation Therapy With or Without Apalutamide in Treating Patients With Recurrent Prostate Cancer, the BALANCE Trial
NCT03371719· Phase 2· NRG Oncology· Source
Recruiting
Seated Balance Using the Indego™
NCT04047992· James J. Peters Veterans Affairs Medical Center· Source
Active, not recruiting
Testing MK-3475 (Pembrolizumab) After Surgery for Localized Muscle-Invasive Bladder Cancer and Locally Advanced Urothelial Cancer
NCT03244384· Phase 3· National Cancer Institute (NCI)· Source
Active, not recruiting
Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy
NCT03055013· Phase 3· National Cancer Institute (NCI)· Source
Active, not recruiting
Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial)
NCT02595944· Phase 3· National Cancer Institute (NCI)· Source
Active, not recruiting
Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
NCT02201992· Phase 3· ECOG-ACRIN Cancer Research Group· Source
Active, not recruiting
Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)
NCT02193282· Phase 3· National Cancer Institute (NCI)· Source
Showing 50 of 53.